Last reviewed · How we verify
CIMERLI (RANIBIZUMAB-EQRN)
CIMERLI (generic name: RANIBIZUMAB-EQRN) is a Vascular Endothelial Growth Factor Inhibitor [EPC] drug developed by SANDOZ INC. It is currently FDA-approved for Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME).
CIMERLI is a vascular endothelial growth factor A inhibitor, classified as an antibody drug. It targets vascular endothelial growth factor A, long form, and is used to treat certain conditions.
At a glance
| Generic name | RANIBIZUMAB-EQRN |
|---|---|
| Sponsor | SANDOZ INC |
| Drug class | Vascular Endothelial Growth Factor Inhibitor [EPC] |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema Following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Myopic Choroidal Neovascularization (mCNV)
Common side effects
- Conjunctival hemorrhage
- Intraocular pressure increased
- Eye pain
- Cataract
- Vitreous floaters
- Vitreous detachment
- Intraocular inflammation
- Foreign body sensation in eyes
- Eye irritation
- Lacrimation increased
- Blepharitis
- Dry eye
Serious adverse events
- Endophthalmitis
- Rhegmatogenous retinal detachment
- Iatrogenic traumatic cataract
Drug interactions
- PDT (Photodynamic Therapy)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CIMERLI CI brief — competitive landscape report
- CIMERLI updates RSS · CI watch RSS
- SANDOZ INC portfolio CI
Frequently asked questions about CIMERLI
What is CIMERLI?
What is CIMERLI used for?
Who makes CIMERLI?
What is the generic name of CIMERLI?
What drug class is CIMERLI in?
What development phase is CIMERLI in?
What are the side effects of CIMERLI?
Related
- Drug class: All Vascular Endothelial Growth Factor Inhibitor [EPC] drugs
- Manufacturer: SANDOZ INC — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Indication: Drugs for Macular Edema Following Retinal Vein Occlusion (RVO)
- Indication: Drugs for Diabetic Macular Edema (DME)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing